Cidara Therapeutics

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Virtual panel discussion will highlight the company's Cloudbreak ® platform and its potential advantages in oncology

Cidara Therapeutics to Host Research and Development Day

SAN DIEGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--Tentarix Biotherapeutics LP, a biotechnology company developing first-in-class targeted, conditional antibody-based multifunctional biotherapies, today announced the formation of a Scientific Advisory Board (SAB) and appointments to its Board of Directors and leadership team. The SAB, initially comprised of three experts in immunology, cancer biology and protein engineering, will provide strategic and scientific counsel to advance the co

Tentarix Biotherapeutics Announces the Strengthening of its Leadership and Advisory Teams

U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch.  Cidara confirmed that the application filing of lead antifungal drug rezafungin as a potential first-.

Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

SAN DIEGO & CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma and Cidara Therapeutics, Inc. (NASDAQ: CDTX) today presented data from the Phase 3 ReSTORE clinical trial of rezafungin in the treatment of candidemia and/or invasive candidiasis at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The data, presented in a late-breaking poster, showed non-inferiority for rezafungin dosed once-weekly compared to caspofungin, the current standard of care, dosed once-d

Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile

SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced that the companies will present new clinical data and analyses of rezafungin, a novel, once-weekly echinocandin in development for the treatment of candidemia and invasive candidiasis and prevention of invasive fungal infections, at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held virtually and in Lisbon, Portugal, from April 23-26, 2022. The new data will be presented in three presentations, including two late-breaking presentations highlighting full results from the global Phase 3 ReSTORE trial and the integrated analyses from the ReSTORE Phase 3 and STRIVE Phase 2 trials.

Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022

CD388 is a drug-Fc conjugate (DFC) from Cidara's Cloudbreak® platform and is designed to transform the standard of care for seasonal influenza prevention

Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 21.21% and 84.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year ended December 31, 2021 and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--Mundipharma and Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has granted rezafungin Promising Innovative Medicine (PIM) designation for the treatment of invasive candidiasis. Invasive candidiasis is a severe, life-threatening systemic Candida infection of the bloodstream and/or deep/visceral tissues. For the MHRA to grant a PIM designation, medicinal product

Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should Know

The FDA has signed off Cidara Therapeutics Inc's (NASDAQ: CDTX) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for influenza. CD388 is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza, added the Company.

FDA Clears Cidara Therapeutics' Phase 1 Trial For Immunotherapeutic Antiviral For Influenza

Cidara intends to initiate the Phase 1 trial in Q1 2022

Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 17,000 shares of its common stock to three new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of December 31, 2021. Each of the stock options has an exercise price of $1.27 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date that occurs during the calendar quarter that includes the Date of Grant, subject to the participant's Continuous Service through each such vesting date. Quarterly Vesting Date means March 10, June 10, September 10 or December 10. The awards are subject to the award holders' continuous service through each vesting date and to the terms and conditions of the company's 2020 Inducement Incentive Plan and its standard forms of grant agreements thereunder.

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cidara Therapeutics Inc (NASDAQ: CDTX) and Mundipharma posted topline data from the ReSTORE Phase 3 trial of rezafungin for candidemia and invasive candidiasis. Rezafungin met the FDA primary endpoint of all-cause mortality at Day 30 and the primary endpoint for the European Medicines Agency (EMA) submission of global cure at Day 14.

Cidara Therapeutics Stock Slides Despite Acing Rezafungin Trial In Fungal Infection

Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Investors need to pay close attention to Cidara Therapeutics (CDTX) stock based on the movements in the options market lately.

Implied Volatility Surging for Cidara Therapeutics (CDTX) Stock Options

Cumberland Pharma

CTI BioPharma

Penny stocks to watch even with Biotech ETFs heading lower today. The post 3 Biotech Penny Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks To Watch With The Stock Market Down Today

Cidara recognized as the top-ranked biotech therapeutics company based on employee feedback Cidara recognized as the top-ranked biotech therapeutics company based on employee feedback

Cidara Therapeutics Named A San Diego Metro Area Top Workplace For The Fifth Consecutive Year

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 0.00% and 95.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Reports Q3 Loss, Tops Revenue Estimates

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2021 and provided an update on its corporate activities and product pipeline.

Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the closing of its previously announced concurrent but separate underwritten public offerings of 17,064,511 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,225,805 shares of common stock, at a price to the public of $1.55 per share and 774,194 shares of its Series X Convertible Preferred Stock at a price to the public of $15.50 per share. The gross proceeds to Cidara from these offerings, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $38.5 million.

Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separate underwritten public offerings of 14,838,706 shares of its common stock at a price to the public of $1.55 per share and 774,194 shares of its Series X Convertible Preferred Stock at a price to the public of $15.50 per share. The gross proceeds to Cidara from these offerings, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $35.0 million.

News for Cidara Therapeutics Stock (CDTX)